BIOCAD Joins the EU. The company plans to enter European market through partnership in Finland. This partner program covers collaboration in education, fundamental sciences and commercial manufacturing. Total investment over 7 years will exceed 25 million euro.
The CEO of BIOCAD – Dmitry Morozov announced: «The main goal of our presence in Turku is mutual collaboration in scientific projects and research in immune-oncology field. BIOCAD covers this area for the long time and will be focused on further development of innovative molecules for the EU»
At this stage, BIOCAD has already developed seven molecules for the European markets, which are used in treatment of oncologic and autoimmune diseases such as melanoma, breast cancer, gastric cancer, kidney cancer, lung cancer, rheumatoid arthritis, and multiple sclerosis, which are very problematic therapeutic areas for Baltic region.
The company creates the new technological working places for the students graduated from the University of Turku. The HR policy of BIOCAD covers collaboration in education and development of young talents.
BIOCAD sees high perspectives in mutual collaboration program covering unmet medical needs of patients.